HKSE - Delayed Quote HKD

Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK)

Compare
1.800
+0.160
+(9.76%)
At close: January 28 at 11:58:55 AM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
163,676.000
163,676.000
251,114.000
403,777.000
324,268.000
Operating Income
-163,676.000
-163,676.000
-251,114.000
-403,777.000
-324,268.000
Net Non Operating Interest Income Expense
3,422.000
3,422.000
3,051.000
287.000
134.000
Pretax Income
-188,820.000
-188,820.000
-230,868.000
-409,825.000
-340,294.000
Net Income Common Stockholders
-175,893.000
-175,893.000
-204,236.000
-361,449.000
-325,523.000
Diluted NI Available to Com Stockholders
-175,893.000
-175,893.000
-204,236.000
-361,449.000
-325,523.000
Basic EPS
-0.72
--
-0.84
-1.64
-1.37
Diluted EPS
-0.72
--
-0.84
-1.64
-1.37
Basic Average Shares
243,417.000
--
243,745.000
220,590.000
237,937.000
Diluted Average Shares
243,417.000
--
243,745.000
220,590.000
237,937.000
Rent Expense Supplemental
17.000
17.000
12.000
--
--
Total Expenses
163,676.000
163,676.000
251,114.000
403,777.000
324,268.000
Net Income from Continuing & Discontinued Operation
-175,893.000
-175,893.000
-204,236.000
-361,449.000
-325,523.000
Normalized Income
-147,271.000
-147,271.000
-204,235.000
-361,449.000
-325,523.000
Interest Income
4,000.000
4,000.000
4,010.000
972.000
190.000
Interest Expense
578.000
578.000
959.000
685.000
56.000
Net Interest Income
3,422.000
3,422.000
3,051.000
287.000
134.000
EBIT
-188,242.000
-188,242.000
-229,909.000
-409,140.000
-340,238.000
EBITDA
-166,887.000
-166,887.000
-209,052.000
-395,906.000
-331,595.000
Reconciled Depreciation
21,355.000
21,355.000
20,857.000
13,234.000
8,643.000
Net Income from Continuing Operation Net Minority Interest
-175,893.000
-175,893.000
-204,236.000
-361,449.000
-325,523.000
Total Unusual Items Excluding Goodwill
-28,622.000
-28,622.000
-1.000
--
--
Total Unusual Items
-28,622.000
-28,622.000
-1.000
--
--
Normalized EBITDA
-138,265.000
-138,265.000
-209,051.000
-395,906.000
-331,595.000
12/31/2020 - 12/23/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

OABIW OmniAb, Inc.
0.4011
+14.60%
 
MNOV MediciNova, Inc.
2.0500
+1.49%
 
OABI OmniAb, Inc.
3.2100
+1.26%
 
ENZC Enzolytics, Inc.
0.0009
0.00%
 
VNDA Vanda Pharmaceuticals Inc.
4.5800
+1.10%
 
ZNTL Zentalis Pharmaceuticals, Inc.
1.6600
-12.17%
 
PPCB Propanc Biopharma, Inc.
25.00
0.00%